{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-110412","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2026-09-24T20:16:39+00:00","discovered_at":"2026-09-24T20:17:12.251996+00:00","generated_at":"2026-09-24T20:17:23.027704+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Rezolute FY26 net loss $77.6M; cash $107.8M; upLIFT positive, sunRIZE under FDA review","bullets":["Cash and investments $107.8M at Jun 30, 2026, down from $167.9M at Jun 30, 2025.","FY2026 net loss $77.6M vs $74.4M FY2025; Q4 net loss $20.5M vs $24.4M year ago.","R&D FY26 $53.8M (down from $61.5M); G&A FY26 $29.2M (up from $18.4M).","upLIFT Phase 3: 7 of 8 enrolled participants met primary endpoint responder criterion; topline results expected before end of 2026.","sunRIZE Phase 3 congenital HI missed primary endpoint; data remains under FDA review; OLE ongoing with improved glycemic control."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-110412","json":"https://secwatch.observer/filing/0001104659-26-110412.json","markdown":"https://secwatch.observer/filing/0001104659-26-110412.md","text":"https://secwatch.observer/filing/0001104659-26-110412.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465926110412/0001104659-26-110412-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465926110412/tm2625842d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-24T20:17:23.027704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}